Фармакогенетические аспекты терапии ингибиторами протонной помпы у больных гастроэзофагеальной рефлюксной болезнью
Диссертация
Существует три состояния мутаций генов цитохрома 2С19, определяющих метаболическую активность в отношении ингибиторов протонной помпы и, в конечном итоге, скорость распада этих препаратов. При этом выявление у больных гомозиготного состояния по дикому типу диктует необходимость увеличения суточных дозировок препаратов, в случае установления мутантного состояния по обеим аллелям достаточно… Читать ещё >
Список литературы
- Алексеенко С.А. Клинико-патогенетические особенности различных видов фармакотерапии у больных с обострением язвенной болезни желудка и двенадцатиперстной кишки. //Дис.. докт. мед. наук. -Хабаровск, 1996. 164 с.
- Аруин Л.И. Апоптоз при патологических процессах в органах пищеварения. //Клин. мед. 2000. Т. 78, № 1. — С. 5−10.
- Аруин Л.И., Григорьев П. Я., Исаков В. А., Яковенко Э. П. Хронический гастрит. — Амстердам, 1993. 362 с.
- Аруин Л.И., Капуллер Л. Л., Исаков В. А. Морфологическая диагностика болезней желудка и кишечника. М.: Триада-Х. — 1998. -483 с.
- Балаж А., Блажек И. Эндогенные ингибиторы клеточной пролиферации. М.: Мир. — 1982. — 304 с.
- Барышников А.О., Шишкин Ю. К. Программированная клеточная смерть (апоптоз). // Рос. онкол. журн., 1996. 1. С. 58−61.
- Битти А.Д. Диагностические тесты в гастроэнтерологии. Пер. с англ. -М.: Медицина. 1995. — 224 с.
- Василенко В.Х., Гребенев А. Л., Шептулин A.A. Язвенная болезнь. (Современные представления о патогенезе, диагностике, лечении). — М.: Медицина, 1987. 288 с.
- Гланц С. Медико-биологическая статистика. М., Практика. — 1998.— 459 с.
- Государственный реестр лекарственных средств в 2-х томах под ред. Р. У. Хабриева. М., 2004.
- П.Григорьев П. Я., Яковенко Э. П. Клиническая гастроэнтерология, М., 2002
- Донцов В.И., Крутысо В. Н., Подколзин A.A. Старение: механизмы и пути преодоления. М.: Биоинформсервис. — 1997. — 122 с.
- Ивашкин В.Т., Трухманов A.C. Болезни пищевода. Москва, Триада. 2000.- 179 с.
- Ивашкин В.Т., Трухманов A.C., Ивашкина Н. Ю. Эффективность нового ингибитора протонной помпы Париета при лечении гастроэзофагеальной рефлюксной болезни // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2000.- N5,-стр.47−51.
- Ивашкин В.Т., Комаров Ф. И., Рапопорт С. И. Краткое руководство по гастроэнтерологии. -М.ЮОО «Издательский дом «М-Вести», 2001.
- Ивашкин В.Т., Шептулин A.A., Макаров Ю. С., Немытин Ю. В. Сравнительная оценка антисекреторной эффективности лосека МАПС, париета и нексиума у больных язвенной болезнью. // Клинические перспективы гастроэнтерологии, гепатологии. № 5, 2002, с. 19−22.
- Ивашкин В.Т., Шептулин A.A., Баранская Е. К., Трухманов A.C., Колмакова О. З. Рекомендации по обследованию и лечению больных с синдромом диспепсии. Пособие для врачей. М., 2001.
- Ионова Т.И., Новик A.A., Сухонос В. А. Понятие качества жизни больных онкологического профиля. // Онкология. 2000. — т.2. — № 12. — С. 25−28.
- Исаков В. А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М.: ИКЦ «Академкнига», 2001. -304 с.
- Калинин A.B. Гастроэзофагеальная рефлюксная болезнь. От патологии к клинике и лечению. // Русский медицинский журнал, 1996. Том 4, № 3.
- Клинические лекции по гастроэнтерологии и гепатологии в 3-х томах под редакцией A.B. Калинина и А. И. Хазанова, М.: ГИУВ МО РФ- ГВКГ им. H.H. Бурденко, 2002.
- Краткое руководство по гастроэнтерологии / под ред. В. Т. Ивашкина, Ф. И. Комарова, С. И. Рапопорта. М.: ООО «Издат дом «М-вести», 2001.-458 с.
- Колпакова Е.В. Качество жизни и артериальная гипертония: роль оценки качества жизни в клинических исследованиях и практической деятельности врача. // Тер. арх. 2000. — № 5. — С. 71−74.
- Колтунов С.С. Течение язвенной болезни двенадцатиперстной кишки при использовании различных видов противорецидивного лечения // Автореферат дис. .канд. мед. наук. Хабаровск, ДВГМУ. — 2000. -С.24.
- Курилович С.А., Решетников В. О. Эпидемиология заболеваний органов пищеварения в Западной Сибири.- Новосибирск, 2000.- 165 с.
- Лопина О.Д. Механизм действия ингибиторов протонного насоса // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2002.- N2, — стр.38−45.
- Маев И.В., Балашова H.H. Современные аспекты терапии гастроэзофагеальной рефлюксной болезни. // Экспериментальная и клиническая гастроэнтерология. 2003, № 1. — С. 5−11.
- МакНелли П.Р. «Секреты гастроэнтерологии"/Пер с англ. М. — Спб.: Бином, Невский диалект, 1999.
- Мартынова Е.А. Молекулярные механизмы апоптоза. (Материалы Академической школы им. A.M. Уголева «Современные проблемы физиологии и патологии пищеварения»). //Рос. журн. гастроэнтерол., гепатол., колопроктол. 1999. — № 6. — С. 75−83.
- Новик A.A. Оценка качества жизни в клинической медицине. // Клин, медицина. 2000. — № 2. — 47.
- Новик A.A., Матвеев С. А., Ионова Т. И. и др. Оценка качества жизни в медицине. // Клинич. медицина. 2000. — № 2. — С. 10 — 13.
- Никонов E.JI. Клинико-патогенетические особенности различных видов антисекреторной терапии у больных кислото-зависимыми заболеваниями. // Дис.. докт. мед. наук. Москва, РГМУ, 2004. — 238 с.
- Орлов В.А., Гиляровский С. Р. Проблемы изучения качества жизни в современной медицине. М. — 1992.
- Осипова В.В. Гастроэзофагеальная рефлюксная болезнь: особенности диагностики и прогнозирования течения эндоскопически негативной формы. // Автореферат дис. .канд. мед. наук. — Саратов. 2002. — С.24.
- Зб.Охлобыстин A.B. Использование внутрижелудочной рН-метрии в клинической практике. Методические рекомендации для врачей. М., 1996.-31 с.
- Пасечников В.Д. // в кн.: Клинические лекции по гастроэнтерологии и гепатологии в 3-х томах под редакцией A.B. Калинина и А. И. Хазанова, М.: ГИУВ МО РФ- ГВКГ им. H.H. Бурденко, 2002
- Пиманов С.И. Эзофагит, гастрит, язвенная болезнь. — М., Триада-Х, 2000
- Симаненков В.И., Захарова Н. В. Применение антисекреторных препаратов при кислото-зависимых заболеваниях. // Гастроэнтерология Санкт-Петербурга, 2002, № 4, С. 30−32.
- Старостин Б.Д. Кислотный индекс пищевода / Материалы 6-го Международного Славяно-Балтийского научного форума «Санкт-Петербург Гастро-2004» // Гастроэнтерология Санкт-Петербурга. — 2004.-№ 2−3.-С. М. 140.
- Тогузова Д. А. Использование суточного мониторирования интрагастральной кислотности в клинической практике (Методические рекомендации). -М.: РГМУ. 1998. — 16 с.
- Трухманов A.C. Гастроэзофагеальная рефлюксная болезнь: клиника, диагностика, лечение // Рос. мед. журн. гастроэнтерол., гепатол., колопроктол. 2001.- Т. 3, № 1. — С. 19−24.
- Ушкалова Е.А., Шугурова И. М. Фармакогенетика ингибиторов протонной помпы. //Фарматека, 2003, № 7, с. 35−40.
- Федеральное руководство для врачей по использованию лекарственных средств (Формулярная система). Вып. II. -М.: 2001 -921 с.
- Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология: основы доказательной медицины (пер. с англ.). М.: МедиаСфера. -1998.- 352 с.
- Хомерики С.Г. Процессы регенерации в слизистой оболочке желудка и канцерогенез. // Росс. журн. гастроэнтерол, гепатол. и колопроктол. -2001.-№ 2.-С. 17- 23.
- Шептулин А.А., Трухманов А. С. Новое в диагностике и лечении гастроэзофагеальной рефлюксной болезни и ахалазии кардии. // Клиническая медицина. 1998.-N5.-cTp.15−19.
- Яковенко А.В. Суточное мониторирование интрагастральной кислотности при язвенной болезни двенадцатиперстной кишки как обоснование выбора антисекреторных препаратов. // Автореферат дис. .канд. мед. наук. Москва. РГМУ- 1993. — С.32.
- Abelo A., Andersson Т.В., Antonsson М. et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. // Drug Metab Dispos. — 2000- 28(8):966−72.
- Adachi K, Katsube T, Kawamura A. et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. // Aliment Pharmacol Ther. — 2000−14(10):1259−66.
- Adithan C, Gerard N, Vasu S, Rosemary J. et al. Allele and genotype frequency of CYP2C19 in a Tamilian population. // Br. J. Clin. Pharmacol. .— 2003- 56(3): 331−3.
- Ambulatory esophageal pH monitoring: practical approach and clinical applications / ed. by Richter J.E. Igaku-Shoin Medical Publishers. 1991. — 229 p.
- Andersson T, Hassan-Alin M, Hasselgren G. et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. // Clin Pharmacoldnet. — 2001 -40(6):411−26.
- Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. // Clin Pharmacokinet. — 1996- 31(l):9−28.
- Aynacioglu A.S., Sachse C., Bozkurt A. et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. // Clin Pharmacol Ther. — 1999- 66(2): 185−92. ••
- Balian J.D., Sukhova N., Harris J.W. et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. // Clin Pharmacol Ther. — 1995- 57(6): 662−9.
- Basci NE, Bozkurt A, Kortunay S. et al. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. // Br. J. Clin Pharmacol. — 1996- 42(6): 771−3
- Beck IT, Champion MC, Lemire S, et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. // Can J Gastroenterol. — 1997- 11 (suppl B):7B-20B.
- Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. // Clin Pharmacokinet. 1997- 32(3):210−58.
- Blaisdell J, Mohrenweiser H, Jackson J. et ai. Identification and functional characterization of new potentially defective alleles of human CYP2C19. // Pharmacogenetics. 2002- 12(9): 703−11.
- Blaser M.J., Ecology of Helicobacter pylori in the human stomach. // J. Clin. Invest. 1997. — Vol. 100. — P.759−62.
- Borsch G. Campylobacter pylori: new and rewened insights into gastritis-associated ulcer disease. // Hepato-gastroenterol. 1987. — Vol. 34. — P. 191−193.
- Bottiger Y, Tybring G, Gotharson E, Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. // Clin Pharmacol Ther. 1997−62(4):384−91.
- Bozina N, Granic P, Lalic Z. et al. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. // Croat Med J. 2003- 44(4): 425−8
- Britzi M, Bialer M, Arcavi L. et al. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. // Ther Drug Monit. 2000- 22(5): 510−6.
- Cahill R.J., Xia H., Kilgallen C. Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation. // Dig. Dis. Sei. -1995. Vol. 40(8). — P.1627−1631.
- Carling L, Axelsson CK, Forssell H. et al. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. // Aliment Pharmacol Ther. 1998- Vol. 12. — p. 985−990.
- Castell DO, Kahrilas PJ, Richter JE. et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. // Am J Gastroenterol. 2002- 97:575−583.
- Cattoretti G., Pileri S., Parravicini C. Antigen unmasking on formalin-fixed, parafin-embedded tissue sections. // J. Pathol. 1993. — Vol. 171. -P.83−98.
- Chang M, Dahl ML, Tybring G. et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. // Pharmacogenetics. 1995- 5(6): 358−63.
- Chang M, Tybring G, Dahl ML. et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.// Br J Clin Pharmacol. 1995- 39(5):511−8.
- Chau TK, Marakami S, Kawai B, Nasu K, Kubota T, Ohnishi A. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma. // Life Sci. 2000 25- 67(14): 1719−24.
- Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. // Pharmacotherapy. 2003−23(4):460−71
- Collins FS, Guttmacher AE. Genetics moves into the medical mainstream. // JAMA. 2001- 14- 286(18):2322−4.
- Courillon-Mallet A. Helicobacter pylori infection and gastric acid secretion. // Gastroenterology Clin Biol. 1997. — Vol. 21(2). — P. 139−46.
- De Morais S.M., Wilkinson G.R., Blaisdell J, Meyer U.A., Nakamura K., Goldstein JA. Identification of a new genetic defect responsible for thepolymorphism of (S)-mephenytoin metabolism in Japanese. // Mol Pharmacol. 1994- 46(4): 594−8.
- Dent J. An evidence-based appraisal of reflux disease management—the Genval Workshop Report. // Gut. 1999- 44(suppl 2):S1-S16.
- Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. // Antimicrob Agents Chemother. 2001- 45(2):382−92.
- Desta Z, Zhao X, Shin JG. et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. // Clin Pharmacokinet, 2002- 41(12): 913−58.
- Dimenas E., Carlsson G. s Glise H. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. // Scand. J. Gastroenterol. 1996. Vol. 221. — P. 813.
- Dupas JL, Houcke P, Samoyeau R. Pantoprazole versus lansoprazole in French patients with reflux esophagitis. // Gastroenterol Clin Biol. 2001- 25:245−250.
- Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. // Aliment Pharmacol Ther. -2001- 15:1729−1736.
- E1-Omar E., Penman J., Ardill J.E. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer diseases. // Gastroenterology. 1995. — Vol. 109. — P. 681−691
- E1-Serag HB, Sonnenberg A: Opposing time trends of peptic ulcer and reflux disease. // Gut. -1998. Vol. 43: 327.
- Enck P., Dubois D., Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). // Scand. J. Gastroenterol. 1999.-Vol. 231.-P.48−54.
- Evans DA, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. //Pharmacogenetics. 1995- 5(2): 64−71.
- Evans W.E. Pharmacogenomics: marshalling the human genome to individualise drug therapy. // Gut. 2003. — 52(Suppl II): iilO—iil 8
- Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. // Annu Rev Genomics Hum Genet.-2001. Vol. 2:9−39.
- Fan X.G., Kelleher D., Fan X.J. Helicobacter pylori increases proliferation of gastric epithelial cells. // Gut. 1996. — Vol. 38. — P. 167−73.
- Feldman M, Burton ME. Histamine 2 receptor antagonists. Standard therapy for acid-peptic diseases.// N Engl J Med. 1990. — Vol. 13- 323(24): 1672−80.
- Ferguson R.J., De Morais S.M., Benhamou S. et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.// J Pharmacol Exp Ther. 1998. — Vol. 284(1): 356−61.
- Fierz W. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? // Med Sci Monit. -2004.-Vol. 10(5):RA111−23.
- Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. //Pharmazie. 2002. — Vol. 57(9):595−601.
- Furuta T, Shirai N, Sugimoto M. et al. Pharmacogenomics of proton pump inhibitors. //Pharmacogenomics. Vol. 2004. — Vol. 5(2):181−202.
- Furuta T., Baba S., Takashima M. Effect of Helicobacter pylori infection on gastric juice pH. // Scand J Gastroenterol. 1998. — Vol. 33(4). — P. 357−63.
- Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. // Eur. J. Clin. Pharmacol. 2003. — Vol. 59(4): 303−12.
- Gerdes J. Cell cycle analysis of a cell proliferation-associated human unclear antigen de-fined by the monoclonal antibody Ki-67. // J. Immunol. -1984.-Vol. 133.-P. 1710.
- Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. // Eur J Gastroenterol Hepatol. — 2001- 13(5): 611−6.
- Glise H., Wiklund I. Health-related quality of life and gastrointestinal disease. // J. Gastroenterol. Hepatol. 2002. — Vol. 17 Suppl. 1. — P. 72−84.
- Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. // Pharmacogenetics. 1994- 4(6): 285−99.
- Goldstein JA, Faletto MB, Romkes-Sparks M. et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.// Biochemistry. 1994. — 22- 33(7): 1743−52.
- Gonzalez HM, Romero EM, Peregrina AA. et al. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. // J Clin Pharmacol. 2003- 43(11): 1211−5.
- Graham D. Helicobacter pylori, Blackwell, 2002, 220 p.
- Guo M., Hay B.A. Cell proliferation and apoptosis. // Current Opinion in Cell Biology. 1999. — 11. — P.745−752.
- Hall P.A., Levison D. A. Assessment of cell proliferation in histological material. // J. Clin. Pathol. 1990. — Vol. 43. — P. 184
- Hamdy SI, Hiratsuka M, Narahara K. et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. // Br J Clin Pharmacol. 2002- 53(6): 596−603.
- Hauser W., Grandt D. Measuring quality of life in gastroenterology -concepts, instruments and problems. // Z. Gastroenterol. 2001. Vol. 39(6). -P. 475−81.
- He N, Yan FX, Huang SL. et al. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population. // Eur J Clin Pharmacol. 2002- 58(1): 15−8. Epub 2002 22.
- Heiander H.F. The normal gastric mucosa. In: Stomach. Ed. By S. Gustavsson, Churchill Livingston, London. 1992. — P. 1−20.
- Helicobacter pylori. Basic mechanisms to clinical cure 2002 edited Hunt R.H. and Tytgat G., 2003, Kluwer Academic Publishers and Axcan Pharma, 538 p.
- Herrlin K, Massele AY, Jande M. et al. Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. // Clin Pharmacol Ther. — 1998- 64(4): 391−401.
- Horai Y, Kimura M, Furuie H. et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes //Aliment Pharmacol Ther. — 2001- 15(6):793−803.
- Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population // Br J Clin Pharmacol. — 1998- 46(5): 499−504.
- Howden CW, Ballard ED, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. // Clin Drug Invest. 2002- 22:99−109.
- Ibeanu GC, Goldstein JA, Meyer U. et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. // J Pharmacol Exp Ther. 1998- 286(3): 1490−5.
- Ingelman-Sundberg M. Implications of polymorphic cytochrome P450-dependent drugs metabolism for drug development. // Drug metabolism and disposition Vol. 29, No. 4, Part 2
- Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. // J. Intern. Med. 2001. Vol. 250(3). -P. 186−200.
- Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole. // Aliment Pharmacol Ther 1999- 13: 27−36.
- Ishizaki T, Sohn DR, Kobayashi K. et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. // Ther Drug Monit. — 1994- 16(2): 214−5.
- Jain KK. Personalized medicine. // Curr Opin Mol Ther. — 2002- 4(6):548−58.
- Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, Rode A CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. // Pharmacogenetics. — 1996- 6(4): 329−39
- Kahrilas PJ. Strategies for medical management of reflux disease.// Baillieres Best Pract Res Clin Gastroenterol. 2000- 14:775−791.
- Kalow W. The genetic defect of mephenytoin hydroxylation. // Xenobiotica. 1986- 16(5): 379−89.
- Kaneko A, Lum JK, Yaviong L. et al. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. // Pharmacogenetics. 1999- 9(5): 58 190.
- Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. //Eur J Clin Pharmacol. 1997- 52(5): 391−6.
- Kearns GL, Winter HS. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics. // J Pediatr Gastroenterol Nutr. -2003- 37 Suppl l: S52−9.
- Kerr J.R.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. // Br. J. Cancer. 1972. — Vol. 26. — P. 239−257.
- Khoda K., Tanaka K., Aiba Y. Role of apoptosis induced by Helicobacter pylori infection in the development of duodenal ulcer. // Gut. 1999. — Vol. 44. — P. 456−462.
- Kim K., Shon J., Park J. et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. // Clin Pharmacol Ther. 2002- 72(l):90−9
- Kimura M, Ieiri I, Mamiya K. et al. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.// Ther Drug Monit. 1998- 20(3): 243−7.
- Kita T, Sakaeda T, Aoyama N. et al. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. // Biol Pharm Bull. 2002- 25(7):923−7.
- Klinkenberg-Knol EC, Nelis F, Dent J. et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. // Gastroenterology. 2000- 118:661−669.
- Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. // Drug Metab Dispos. 1997- 25(7):853−62.
- Koyama E, Tanaka T, Chiba K. et al. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. // J Clin Psychopharmacol. 1996- 16(4): 286−93.
- Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4-hydroxylation in an extended Japanese population. // Clin Pharmacol Ther. 1996- 60(6): 661−6.
- Lachman L., Howden C.W. Twenty-Four-Hour Intragastric pH: Tolerance Within 5 Days of Continuous Ranitidine Administration. // Am J Gastroenterol. 2000- 95: 57−61.
- Lamba J, Dhiman R, Kohli K. Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects. // Clin Pharmacol Ther. 1998- 63(4): 422−7
- Leers M. P., W. Kolgen, V. Bjorklund et al. Immunocytochemical detection and mapping of a cytokeratin-18 neoepitope exposed during early apoptosis. // J. Pathol. 1999. 187:567.
- Levy A., Banwait K.S., DiMarino A. et al. Utility of twenty-four esophageal pH monitoring in patients with persistent symptoms on PPI therapy. // Gastroenterology. 2004: 4, suppl.2, A-19.
- Lin J.H., Lu A.Y.H. Role of Pharmacokinetics and Metabolism in Drug Discovery and Development// Pharmacological reviews. — 1997. — Vol. 49, Issue 4, 403−449.
- Lipkin M. Gastric cell regeneration.// Arch. Fr. Mai. App. Dig. -1972.-Vol. 61(11).-P. 691−3.
- Lipkin M. Proliferation and differentiation of gastrointestinal cells. // Physiol Rev. 1973. Vol. 53(4). — P.891−915.
- Lu Y.H. Drug-metabolism research challenges in the new millennium. // Drug metabolism metabolism and disposition, 2002, Vol. 26, No. 12.
- Lundell L, Miettinen P, Myrvold HE. et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. // J. Am Coll Surg. 2001- 192:172−179.
- Lynch D.A.F., Mapstone N.P., Lewis F. Correlation between cell proliferation in Helicobacter pylori associated gastritis and histological scoring using the Sidney system. // Gut. 1993. — Vol. 34. — P. 197.
- Malfertheiner P., Megraud F., O’Morain C. Current concepts in the management of Helicobacter pylori infection the Maastricht II — 2000 Consensus Report. // Aliment. Pharmacol. Ther. — 2002. — Vol. 16(2). — P. 167−80.
- Mamiya K, Hadama A, Yukawa E. et al. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. // Eur J Clin Pharmacol. 2000- 55(11−12): 821−5.
- Manning F.C.R., Patierno S.R. Apoptosis: inhibitor or instigator of carcinogenesis? // Cancer Invest. 1996. — Vol. 14. — P. 455−465.
- Marandi T, Dahl ML, Kiivet RA. et al. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population. — Pharmacol Toxicol. 1996- 78(5): 303−7
- Marinac JS, Balian JD, Foxworth JW. et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. // Clin Pharmacol Ther. 1996- 60(2): 138−44
- Marshall B. Pioneers of Helicobacter pylori-nfection. — 2002. — 3241. P
- Masimirembwa C, Bertilsson L, Johansson I. et al. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. // Clin Pharmacol Ther. 1995- 57(6): 656−61.
- McCormick D., Chong H.M., Hobbs C. Detection of the Ki-67 antigen in fixed and wax-embedded sections with monoclonal antibody MIB-1. // Histopathology. 1993. Vol. 22. — P. 355−360.
- Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics?// Clin Pharmacokinet. 2002- 41(5):-a 329−42.
- Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. // Annu Rev Pharmacol Toxicol. -1997- 37:269−96.
- Modlin I., Sachs G. Acid-related diseases. — 2000. — p.870.
- Moss SF. Helicobacter pylori and apoptosis. // Yale J. Biol. Med. -1998. Vol. 71(2). -P.53−61.
- Moss SF. The carcinogenic effect of H. pylori on the gastric epithelial cell. // J. Physiol. Pharmacol. 1999. — Vol. 50(5). — P. 847−56.
- Murphy MS. Growth factors and the gastrointestinal tract. // Nutrition.- 1998. Vol. 14(10). — P.771−74.
- Nelson DR, Koymans L, Kamataki T et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. // Pharmacogenetics. 1996- 6(l):l-42.
- Niemcryk S., Joshua-Gotlib S., Levine D. The outpatient experience of GERD patients in US: An analysis of the 1998−2000 National ambulatory medical care.// Gastroenterology. — 2004, 126: 4, Suppl.2, S1213.
- Nowak MP, Sellers EM, Tyndale RF. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies.// Clin Pharmacol Ther. — 1998- 64(4): 378−83.
- Pollock BG, Perel JM, Kirshner M. et al. S-mephenytoin 4-hydroxylation in older Americans. // Eur J Clin Pharmacol. —1991- 40(6): 609−11.
- Potten C.S. Stem cells in gastrointestinal epithelium: numbers, characteristics and death. // Philos. Trans. R. Soc. Lond. B. Biol. Sci. -1998. Vol. 353(1370). — P. 821−30.
- Quigley EM. New developments in the pathophysiology of gastroesophageal reflux disease (GERD): implications for patient management. // Aliment Pharmacol Ther. — 2003- 17 Suppl 2:43−51.
- Rampal P., Martin C., Marquis P. et al. A quality of life study in five hundred and eighty-one duodenal ulcer patients. // Scand. J. Gastroenterol.- 1994.-Vol. 29.-P. 44−51.
- Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. // Eur J Gastroenterol Hepatol. — 2001- 13 Suppf l: S43−7.
- Roh HK, Dahl ML, Johansson I. et al. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. // Pharmacogenetics. — 1996- 6(5): 441−7.
- Roh HK, Dahl ML, Tybring G. et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. // Pharmacogenetics. 1996- 6(6): 547−51.
- Romkes M, Faletto MB, Blaisdell JA. et al. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. //Biochemistry. 1991(2) — 30(13): 3247−55.
- Rost KL, Brosicke H, Brockmoller J. et al. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-N-3-methyl.-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. // Clin Pharmacol Ther. 1992- 52(2): 170−80.
- Sagar M, Bertilsson L, Stridsberg M. et al. Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. // Aliment Pharmacol Ther. 2000- 14(11): 1495−502.
- Saitoh T, Fukushima Y, Otsuka H. et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. // Aliment Pharmacol Ther. 2002- 16(10):1811−7.
- Sanz EJ, Villen T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. // Clin Pharmacol Ther. 1989- 45(5): 495−9.
- Sata F, Sapone A, Elizondo G. et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. // Clin Pharmacol Ther. 2000- 67(l):48−56.
- Schwartz JB. The influence of sex on pharmacokinetics.// Clin Pharmacokinet. 2003- 42(2): 107−21.
- Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. // Aliment Pharmacol Ther. 2001- 15:227−31.
- Shaw M., Talley N.J., Adlis S. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population.// Aliment. Pharmacol. Ther. 1998. — Vol. 12(11).-P. 1067−78.
- Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. // Yale J Biol Med. 1999- 72(2−3):81−92.
- Spechler SJ, Lee E, Ahnen D. et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. // JAMA. 2001- 285:2331−2338.
- Stendal C. Practical guide to gastrointestinal function testing. Blackwell Science. 1997. — 280 p.
- Sviri S, Shpizen S, Leitersdorf E. et al. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.// Clin Pharmacol Ther. 1999- 65(3): 275−82
- Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. //Pharmacogenetics. 1996- 6(3): 265−7.
- Tassaneeyakul W., Tawalee A., Tassaneeyakul W. et al. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.// Pharmacogenetics. 2002- 12(3): 221−5.
- Tsuneoka Y, Fukushima K, Matsuo Y. et al. Genotype analysis of the CYP2C19 gene in the Japanese population. // Life Sci. 1996- 59(20): 17 115.
- Vermes I., Haanen C. Apoptosis and programmed cell death in health and disease. // Adv. Clin. Chem. 1994. Vol. 31. — P. 177−246.
- Vivian EM, Thompson MA. Pharmacologic strategies for treating gastroesophageal reflux disease. // Clin Ther. 2002- 22:654−672.
- Wagner S., Beil W., Westermann J., Logan R.P. Regulation of gastric epithelial cell growth by Helicobacter pylori: evidence for a major role of apoptosis. // Gastroenterology. 1997. — Vol. 13(6). — P. 1836−47.
- Wallace JL, Granger DN. The cellular and molecular basis of gastric mucosal defense. // FASEB J. 1996. — Vol. 10(7). — P. 731−40.
- Wanwimolruk S, Bhawan S, Coville PF. et al. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. // Eur J Clin Pharmacol. 1998- 54(5): 431−5.
- Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey: Manual and interpretation guide. Lincoln, RI: Quality Metric Inc., 2000.
- Wedlund PJ. The CYP2C19 enzyme polymorphism. // Pharmacology -2000- 61: 174−83.
- Weinshilboum R. Inheritance and Drug Response. // NEJM. 2003. 348- 6.
- Whittle B.J.R. Protective mechanisms of the gastric mucosa. In: Gustsavsson S., Kumar D., Graham D. Y, eds. The stomach. Edinburgh: Churchill Livingstone, 1992. P.81−101.
- Whittle B.J.R., Vane J.R. Prostanoids as regulators of gastrointestinal function. In: Johnson L.R., Christiansen I, Jackson M.I., Jacobson E.D., Walsh J.H., editors. Physiology of the gastrointestinal tract. New York: Raven, 1987. P. 143−80.
- Wilhelmsen I. Quality of life in upper gastrointestinal disorders. // Scand. J.Gastroenterol. 1995. — Vol. 211. — P.21−25.
- Willis P., Lynch D.A.F., Prescott R., Lamonby S. Cell proliferation in the postsurgical stomach, dietary salt, and the effect of H. pylori eradication. // J. Clin. Pathol. 1999. — Vol. 52. — P.665−669.
- Wong W.M., Wright N.A. Cell proliferation in gastrointestinal mucosa. //J. Clin. Pathol. 1999. — Vol. 52. — P.321−333.
- Wright N., Goodlad R. Measurement of morphokinetic status in experiments on intestinal adaptation. // Gut. 1996. — Vol. 38(3). — P. 4745.
- Wrighton SA, Stevens JC, Becker GW. et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation.// Arch Biochem Biophys. 1993- 306(1): 240−5.
- Xie HG, Huang SL, Xu ZH. et al. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population. // Pharmacogenetics. 1997- 7(2): 115−9.
- Xie HG, Kim RB, Stein CM. et al. Genetic polymorphism of (S> mephenytoin 4'-hydroxylation in populations of African descent. // Br J Clin Pharmacol. 1999- 48(3): 402−8.
- Xie HG, Stein CM, Kim RB. et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. // Pharmacogenetics. 1999- 9(5): 539−4
- Xie HG. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population.// Life Sci. 2000. — Vol. 25- 66(14): PL175−81.
- Yacavone R.F., Locke G.R. 3rd, Provenzale D.T., Eisen G.M. Quality of life measurement in gastroenterology: what is available? // Am. J. Gastroenterol. 2001. — Vol. 96(2). — P. 285−97.
- Yao TW, Zeng S, Wang TW. et al. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC. // Biomed Chromatogr. 2001. — Vol. 15(1): 9−14.